Severe hypersensitivity pneumonitis associated with everolimus therapy for neuroendocrine tumour: a case report.
BACKGROUND
Novel therapeutic agents are currently being investigated for neuroendocrine tumour treatment.


METHODS
We report here on the case of a patient presenting with hypersensitivity pneumonitis while being treated with everolimus, a mammalian target of rapamycin (mTOR) inhibitor.


CONCLUSIONS
Side effects of everolimus should be familiar to clinicians, including nonspecialists, and be monitored carefully to allow for prompt management.
Camille
C
Sibertin-Blanc
Emmanuelle
E
Norguet
Muriel
M
Duluc
Guillaume
G
Louis
Jean-François
JF
Seitz
Assistance Publique - Hôpitaux de Marseille, Service d'oncologie digestive, Hôpital Timone, Université de la Méditerranée, Marseille, France. laetitia.dahan@mail.ap-hm.fr.
Laetitia
L
Dahan
D000542:Alveolitis, Extrinsic Allergic / Q000139:chemically induced* / Q000473:pathology; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000068338:Everolimus; D006801:Humans; D007421:Intestine, Small / Q000187:drug effects / Q000473:pathology; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D008875:Middle Aged; D018358:Neuroendocrine Tumors / Q000188:drug therapy* / Q000473:pathology; D020123:Sirolimus / Q000009:adverse effects / Q000031:analogs & derivatives*
D000970:Antineoplastic Agents; D000068338:Everolimus; D020123:Sirolimus